US FDA clarifies regulatory authority for human dura mater
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration has amended its device regulations to clarify that all human dura mater recovered after 25 May 2005 is subject to a rule governing human cell, tissue, and cellular and tissue-based products (HCT/Ps) rather than to medical device regulations.
You may also be interested in...
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.